These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 19929225)

  • 1. Paracentesis in ovarian cancer: a study of the physiology during free drainage of ascites.
    Decruze SB; Macdonald R; Smith G; Herod JJ
    J Palliat Med; 2010 Mar; 13(3):251-4. PubMed ID: 19929225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian cancer and ascites: A questionnaire on current management in the United kingdom.
    Macdonald R; Kirwan J; Roberts S; Gray D; Allsopp L; Green J
    J Palliat Med; 2006 Dec; 9(6):1264-70. PubMed ID: 17187534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites.
    Easson AM; Bezjak A; Ross S; Wright JG
    Ann Surg Oncol; 2007 Aug; 14(8):2348-57. PubMed ID: 17505860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer.
    Gotlieb WH; Feldman B; Feldman-Moran O; Zmira N; Kreizer D; Segal Y; Elran E; Ben-Baruch G
    Gynecol Oncol; 1998 Dec; 71(3):381-5. PubMed ID: 9887235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Supportive care for malignant ascites in palliative phase: Place of paracentesis and diuretics].
    Gamblin V; Da Silva A; Villet S; El Hajbi F
    Bull Cancer; 2015 Nov; 102(11):940-5. PubMed ID: 26477275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of clinical guidelines on paracentesis for ascites related to malignancy.
    Stephenson J; Gilbert J
    Palliat Med; 2002 May; 16(3):213-8. PubMed ID: 12046997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer.
    Harding V; Fenu E; Medani H; Shaboodien R; Ngan S; Li HK; Burt R; Diamantis N; Tuthill M; Blagden S; Gabra H; Urch CE; Moser S; Agarwal R
    Br J Cancer; 2012 Sep; 107(6):925-30. PubMed ID: 22878372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peritoneal catheter site metastasis in a patient with advanced ovarian cancer.
    Ramirez I; Bansal N; Hoffman M
    Am J Hosp Palliat Care; 2012 May; 29(3):241-2. PubMed ID: 21606122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Procedures for Malignant Ascites in a Palliative Care Outpatient Clinic.
    Korpi S; Salminen VV; Piili RP; Paunu N; Luukkaala T; Lehto JT
    J Palliat Med; 2018 Jun; 21(6):836-841. PubMed ID: 29489450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Ultrasound-Guided Therapeutic Paracentesis in an Outpatient Transitional Care Program: A Case Series.
    Wang J; Khan S; Wyer P; Vanderwilp J; Reynolds J; Bethancourt B; Ota KS
    Am J Hosp Palliat Care; 2018 Sep; 35(9):1256-1260. PubMed ID: 29400065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of symptomatic ascites in hospice patients with paracentesis: a case series report.
    Zama IN; Edgar M
    Am J Hosp Palliat Care; 2012 Aug; 29(5):405-8. PubMed ID: 21998439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and future options in the treatment of malignant ascites in ovarian cancer.
    Woopen H; Sehouli J
    Anticancer Res; 2009 Aug; 29(8):3353-9. PubMed ID: 19661355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of permanent peritoneal ports for the management of recurrent malignant ascites.
    Coupe NA; Cox K; Clark K; Boyer M; Stockler M
    J Palliat Med; 2013 Aug; 16(8):938-40. PubMed ID: 23734592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient experience of non-malignant ascites and its treatment: a qualitative study.
    Day R; Hollywood C; Durrant D; Perkins P
    Int J Palliat Nurs; 2015 Aug; 21(8):372-9. PubMed ID: 26312532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant Ascites: Validation of a Novel Ascites Symptom Mini-Scale for Use in Patients With Ovarian Cancer.
    Eitan R; Raban O; Tsoref D; Jakobson-Setton A; Sabah G; Salman L; Yeoshua E; Ben-Haroush A
    Int J Gynecol Cancer; 2018 Jul; 28(6):1162-1166. PubMed ID: 29664840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
    Sjoquist KM; Espinoza D; Mileshkin L; Ananda S; Shannon C; Yip S; Goh J; Bowtell D; Harrison M; Friedlander ML
    Gynecol Oncol; 2021 May; 161(2):374-381. PubMed ID: 33637349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Low Volume Drainage of Ascites Associated With Improved Survival in Digestive System Cancer Patients With Malignant Ascites?-A Retrospective Cohort Study.
    Hoshino S; Takagi Y; Fukagawa T; Sano K; Seki N; Hashiguchi Y; Aruga E
    J Palliat Care; 2023 Oct; 38(4):473-480. PubMed ID: 37093798
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term semi-permanent catheter use for the palliation of malignant ascites.
    Brooks RA; Herzog TJ
    Gynecol Oncol; 2006 May; 101(2):360-2. PubMed ID: 16499957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma.
    Hirte HW; Miller D; Tonkin K; Findlay B; Capstick V; Murphy J; Buckman R; Carmichael J; Levine M; Hill W
    Gynecol Oncol; 1997 Jan; 64(1):80-7. PubMed ID: 8995552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathogenesis and management of refractory malignant ascites].
    Saâda E; Follana P; Peyrade F; Mari V; François E
    Bull Cancer; 2011 Jun; 98(6):679-87. PubMed ID: 21636346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.